Oral and Sublingual B12 in Pernicious Anemia

Sublingual B12 raises blood numbers. It has never been shown to protect a single nerve. There is no reason to think it prevents permanent nerve damage.

Contents

The Letter
The Danger of Pernicious Anemia
The Absorption Pathway
Passive Diffusion and Its Limits
Utilization Can Still Fail
Serum B12 Is No Answer
Two Decades of Studies, But of WHAT?
The Tissue Sink
The Neurologically Damaged Population
The Question Still Unanswered
References

The Letter

The claim that sublingual B12 is adequate for pernicious anemia originates with a single study published as a letter in The Lancet in 1999. The study involved eighteen patients, had no control group, and followed them for less than 2 weeks. It was written by a gastroenterologist whose published work over more than two decades had centered on bezoars, drug-induced esophageal ulcers, and other gastrointestinal conditions. The 1999 letter on sublingual B12 measured one outcome: whether serum B12 levels rose after sublingual administration. They did.

The Danger of Pernicious Anemia

The danger of pernicious anemia is not about serum levels. It’s about destruction of the nervous system. That damage can show up differently from one person to the next: spinal cord degeneration, peripheral neuropathy, balance problems, brain fog, anxiety, depression. It can advance while blood tests look normal. Anemia is fully reversible. Nerve damage, left uncorrected, may not be.

The Absorption Pathway

Vitamin B12 absorption is a multi-step process. Stomach acid and pepsin release B12 from food proteins. Haptocorrin binds it in the stomach for transport. Pancreatic enzymes then release it again in the small intestine so intrinsic factor can bind it next. Receptors in the terminal ileum recognize the intrinsic factor–B12 complex and move it into the body. Transcobalamin carries B12 through the bloodstream, and cells take it up through the CD320 receptor. Inside the cell, B12 is converted into its active coenzyme forms — methylcobalamin and adenosylcobalamin — which the nervous system requires for myelin maintenance and nerve function.

Pernicious anemia was originally identified by its clinical picture of severe anemia combined with neurological injury, before the absorption mechanism was known. In current diagnostic coding and clinical practice, the diagnosis is tied to autoimmune destruction of parietal cells leading to intrinsic factor deficiency and failure of the normal ileal absorption pathway. Passive diffusion across the intestinal lining provides an alternative route that does not require intrinsic factor. This is the basis for high-dose oral and sublingual B12 raising serum levels without injections.

Passive Diffusion and Its Limits

The larger and ongoing problem, however, is whether B12 can be properly utilized once it reaches tissues. Getting B12 into the bloodstream through passive diffusion is only the first stage. The B12 must still bind to transport proteins, reach target tissues including nerve cells, enter those cells through the CD320 receptor, and be converted into active coenzyme forms inside the cells. None of these later steps is guaranteed simply because the molecule crossed the gut wall.

Utilization Can Still Fail

Several points in this utilization pathway can fail independently of serum levels. The CD320 receptor on cell surfaces is required for uptake of B12 bound to transcobalamin. Dysfunction or blockade of this receptor (whether genetic or acquired, such as through autoantibodies) can prevent B12 from entering nerve cells even when serum B12 is normal or high. Similarly, defects in intracellular processing — including release of B12 from lysosomes inside cells or conversion into its active coenzyme forms — can produce functional B12 deficiency and neurological damage while serum values appear reassuring. These intracellular metabolism defects often present with neurological symptoms and metabolic abnormalities despite normal serum B12, because the problem lies in utilization inside cells rather than absorption or blood transport.

Serum B12 Is No Answer

Serum B12 measures the amount of vitamin circulating in the bloodstream at the time of the blood draw. It does not show whether that B12 reaches nerve cells, is taken up by them through the relevant receptors, or is converted into the active coenzyme forms required for nerve function and repair. In pernicious anemia, serum B12 levels can be normal, low-normal, or even very high while functional deficiency at the tissue level and neurological damage continue. This occurs because passively absorbed B12 may raise circulating levels without ensuring adequate delivery or utilization inside nerve cells, especially when tissue demand is elevated due to existing nerve injury. Serum values alone therefore cannot confirm that neurological protection is occurring.

Two Decades of Studies, But of WHAT?

In the more than twenty-five years since that letter, larger studies and meta-analyses expanded the number of patients examined while keeping the same primary measures. Two of the earliest studies in this body of work made an informal attempt: clinicians noted whether symptoms like paresthesia or memory loss seemed to improve, and one used a basic mental status exam. Neither used a validated neurological scale, a nerve conduction study, or any standardized method, and neither was designed to assess neurological recovery as a primary outcome. No study since has repeated even that attempt. Every study since has tracked serum B12, homocysteine, and methylmalonic acid, and nothing else.

A treatment approach evaluated entirely on biochemical markers in the blood has never been evaluated on the outcome that defines the disease’s danger. The claim that oral or sublingual B12 is an adequate replacement therefore rests on evidence that has not addressed the central clinical problem.

This is where the research on oral and sublingual B12 stops. Every study measures serum B12 or related biochemical markers and goes no further. None determine whether passively absorbed B12 reaches nerve tissue in sufficient quantity and in usable form to prevent, stabilize, or reverse neurological injury. The studies answer whether B12 can enter the circulation without intrinsic factor. They do not answer whether that is enough to protect the nervous system when later utilization steps may be impaired. These are two different questions, and only the first has been studied.

The teams running this research are internists, biochemists, and statisticians. One of the most recent meta-analyses on this exact question was conducted by a team of dentists. Neurology does not appear in the room.

Later research added more biochemical markers: methylmalonic acid, homocysteine, holotranscobalamin. Normalizing these markers proves nothing about whether B12 is reaching nerve tissue and functioning there. Holotranscobalamin comes closest, since it isolates the fraction of circulating B12 that’s actually bioavailable to cells, but even that is a blood measurement. It still stops at the same wall every other marker stops at: it cannot show what happens after the molecule reaches the cell.

The Tissue Sink

Patients with active neurological involvement face an additional problem. Damaged or repairing nerve tissue has increased demand for B12 to support myelin maintenance and nerve repair. This creates a higher draw on available B12 at the tissue level. Passive diffusion delivers only a small percentage of an oral or sublingual dose into the bloodstream. For patients with mild deficiency and no significant neurological injury, that limited amount may be sufficient to maintain serum levels. For patients with ongoing nerve damage, the same amount may fall short because the injured tissue acts as a sink, consuming B12 faster than passive diffusion can reliably replenish it.

Supporting evidence for this increased demand comes from mechanistic understanding of B12’s role in myelin synthesis, animal models showing elevated B12 requirements during neurological stress or injury, and clinical observations in B12 deficiency states with neurological complications.

In practice, this means that for some patients with neurological involvement, the only way to determine whether intramuscular B12 is needed is to conduct a therapeutic trial of injections while monitoring symptoms and clinical response. Biochemical markers cannot reveal whether passively absorbed B12 is meeting tissue demand at the sites of injury.

The Neurologically Damaged Population

This population — patients with significant neurological involvement — has never been isolated or studied separately in the oral and sublingual B12 research. Every major study and meta-analysis has pooled patients with and without neurological symptoms, then reported average biochemical responses. An average response across that mixed group reveals nothing about whether the patients who need the most B12 are actually receiving enough at the sites of injury.

The Question Still Unanswered

There is no reason to think that oral or sublingual B12 protects the nervous system in pernicious anemia. The studies, with two early and methodologically informal exceptions, never measured neurological outcomes, and even those exceptions were never built on or repeated. They only measured what happened to blood levels. Pernicious anemia damages nerves, and that damage can continue even when the blood tests look better. More than twenty-five years and a growing pile of larger studies later, the field still has not asked or answered the one question that matters: whether this regimen protects the patient’s nervous system. It has only ever answered the question posed in an eighteen-patient letter with no control group and two weeks of follow-up. Prescribing oral or sublingual B12 to a patient with neurological involvement and calling it adequate treatment is a decision made without evidence.